VolitionRx Limited, a multinational epigenetics company, has inked a global agreement with Nu.Q Vet test. The global supply agreement makes VolitionRx the worldwide provider of the Nu.Q® Vet Cancer Test through its reference laboratory network for cancer indications in animal health.
According to a clinical study conducted by Volition and Texas A&M University researchers published in August 2022, the cancer test detected 76% of systemic cancers at 97% specificity versus control.
There are approximately 84 million pet dogs in the U.S. and just under 50% of dogs will have at least one veterinary care visit per year. Volition said in its news release that this provides an incredible opportunity to screen senior dogs over seven years of age and breeds at risk of cancer.
"The Nu.Q Vet Cancer Test was developed with the goal of providing an accessible and affordable screening test to aid early detection,” said Dr. Tom Butera, chief executive officer of Volition Veterinary Diagnostics Development LLC.
“This supply agreement is an exciting moment for Volition as we continue to commercialize our Nu.Q technology within the companion animal healthcare sector and capitalize on what we believe to be significant mass market opportunities,” he said.
Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition's Nu.Q® technology go to: www.volition.com